Waters to open analytical lab in UK biohub

By .

- Last updated on GMT

Former AstraZeneca R&D site in Alderly Park, Cheshire, is now  home to over 100,000 sq m of scientific laboratory space
Former AstraZeneca R&D site in Alderly Park, Cheshire, is now home to over 100,000 sq m of scientific laboratory space

Related tags: High performance liquid chromatography, Chromatography

Waters Corporation will offer an open access analytical laboratory and technology support  to biotechs based at a former AstraZeneca site in the UK.

Alderly Park, near Manchester, UK, was sold off by AstraZeneca to Machester Science Parks – a public-private partnership – in 2014​, and yesterday analytical equipment and technology firm Waters announced it has struck an agreement to launch an open access analytical laboratory there.

“This laboratory is a dedicated Open Access Laboratory, for the benefit of all companies located in the BioHub at Alderley Park [known as BioCity],”​ company spokesman Chris Orlando told this publication.

“Scientists on the site will gain access to cutting edge Waters capabilities through the Open Access facility which will be managed and run by BioCity, on a fee-for-sample/time/service basis. Support on the use of the facility, and the technology available, will be provided by an experienced laboratory manager.”

The firm already has its mass spectrometry headquarters and demonstration laboratory in nearby Wilmslow, but this new facility will focus on providing “cost-effective access to the kinds of cutting edge analytical technologies which underpin modern life and health sciences research,”​ he continued.

“Many, if not all, the companies at BioHub are engaged in cutting edge, and diverse, research and development. Close engagement with companies using the facility will give Waters a deeper insight into their needs and challenges.”

The firm’s Ultra Performance Liquid Chromatography (UPLC) systems, mass spectrometry (MS) and informatics technologies will be available at the new laboratory when it opens early this year, as will a nuclear magnetic resonance (NMR) system provided by Manchester Science Partnerships.

Related news

Related products

show more

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Related suppliers

Follow us

Products

View more

Webinars